Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add filters








Year range
1.
Rev. méd. Chile ; 139(1): 89-99, ene. 2011. ilus
Article in Spanish | LILACS | ID: lil-595271

ABSTRACT

Tamoxifen is used as an adjuvant therapy to reduce breast cáncer recurrence among women with estrogenreceptor positive tumors. Antidepressants are also com-monly used in such women, to treat depression or to manage hotflush.es, afrequent tamoxifen secondary effect. Some antidepressants couldpotentially inhibit cytochrome P450 2D6, required to actívate tamoxifen, interfering with its action. Although there is not a clear cut directive on the subject, it is nowadays recommended to treat women with antidepressants with the lower cytochrome P450 2D6 inhibition potential to avoid apossible antagonism that may reduce tamoxifen s prevention of breast cáncer recurrence at least in some patients with CYP2D6 genetic variation. The recommended antidepressants are desvenlafaxine, milnacipran, venlafaxin, escitalopram and citalopram.


Subject(s)
Female , Humans , Antidepressive Agents/adverse effects , Breast Neoplasms/drug therapy , /antagonists & inhibitors , Estrogen Antagonists/metabolism , Tamoxifen/metabolism , Antidepressive Agents/pharmacology , /genetics , Drug Interactions
SELECTION OF CITATIONS
SEARCH DETAIL